Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

Last updated: May 5, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Active tDCS

Sham tDCS

Clinical Study ID

NCT05092516
2021P002953
  • Ages 18-65
  • All Genders

Study Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ability to provide informed consent

  • A diagnosis of PASC as indicated by past COVID-19 infection, and persistentsymptoms, including 'brain fog', confusion, short-term memory deficits, troubleconcentrating, delirium, difficulties in multitasking.

Exclusion

Exclusion Criteria:

  • History of epilepsy

  • Metallic implants in the head and neck,

  • Brain stimulators

  • Pacemakers

  • Pregnancy

  • Active substance dependence (except for tobacco)

  • Premorbid major neurological illness

  • Severe mental illness (e.g., bipolar disorder, schizophrenia)

  • Attention Deficit Hyperactivity Disorder

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Active tDCS
Phase:
Study Start date:
June 07, 2022
Estimated Completion Date:
September 15, 2025

Connect with a study center

  • Massachusetts General Hospital

    Charlestown, Massachusetts 02129
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.